953080-29-0

Basic information

• Product Name: 5-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxy-pyrimidin-4-yl)-1-methyl-2,3-dihydro-1H-indole-2-carboxylic acid ethyl ester
• Synonyms: 5-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxy-pyrimidin-4-yl)-1-methyl-2,3-dihydro-1H-indole-2-carboxylic acid ethyl ester
• CAS NO: 953080-29-0
• Molecular Weight: 501.412
• Mol File: 953080-29-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 5-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxy-pyrimidin-4-yl)-1-methyl-2,3-dihydro-1H-indole-2-carboxylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxy-pyrimidin-4-yl)-1-methyl-2,3-dihydro-1H-indole-2-carboxylic acid ethyl ester(953080-29-0)
• EPA Substance Registry System: 5-(6-(2-(2,4-dichlorophenyl)ethylamino)-2-methoxy-pyrimidin-4-yl)-1-methyl-2,3-dihydro-1H-indole-2-carboxylic acid ethyl ester(953080-29-0)

Safety Data

• Hazardous Substances Data: 953080-29-0(Hazardous Substances Data)

Upstream product

• 91844-20-1 5-bromo-1-methyl-1H-indole-2-carboxylic acid ethyl ester 
• 953080-08-5 5-bromo-1-methyl-2,3-dihydro-1H-indole-2-carboxylic acid ethyl ester 
• 52516-13-9 2-(2,4-dichloro-phenyl)-ethylamine 
• 1074-40-4 4,6-dichloro-2-methoxypyrimidine 

Relevant articles and documents

2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed to a compound of formula (I) wherein R1 and R2 are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the prodrug, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds of the invention in admixture with a pharmaceutically acceptable carrier, a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which are generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound of the invention.